Lyell Immunopharma, Inc. (LYEL)
| Market Cap | 279.31M +124.2% |
| Revenue (ttm) | 31,000 -52.3% |
| Net Income | -246.41M |
| EPS | -13.06 |
| Shares Out | 23.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,677 |
| Open | 12.99 |
| Previous Close | 13.05 |
| Day's Range | 11.70 - 13.51 |
| 52-Week Range | 8.46 - 45.00 |
| Beta | -0.09 |
| Analysts | Strong Buy |
| Price Target | 42.20 (+252.55%) |
| Earnings Date | May 6, 2026 |
About LYEL
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy random... [Read more]
Financial Performance
In 2025, Lyell Immunopharma's revenue was $36,000, a decrease of -40.98% compared to the previous year's $61,000. Losses were -$274.45 million, -19.98% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LYEL stock is "Strong Buy." The 12-month stock price target is $42.2, which is an increase of 252.55% from the latest price.
News
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor ...
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor ...
Lyell Immunopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum
The company is advancing next-generation cell therapies with strong clinical data for ronde-cel in lymphoma and a novel dual CAR for colorectal cancer. Regulatory and manufacturing strategies are robust, with pivotal data and major updates expected soon. Cash reserves support operations through key milestones.
Lyell Immunopharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Ronde-cel leads the CD19/CD20 CAR T-cell space with strong efficacy, safety, and manufacturing readiness, outpacing competitors and targeting a large third-line lymphoma market. The colorectal cancer program shows promising, durable responses. Key pivotal data updates and regulatory milestones are expected this year and next.
Lyell Immunopharma Announces Participation in May Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (...
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027...
Lyell Immunopharma Quarterly report: Q1 2026
Lyell Immunopharma has published its Q1 2026 quarterly earnings report on May 6, 2026.
Lyell Immunopharma Earnings release: Q1 2026
Lyell Immunopharma released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Lyell Immunopharma initiated with an Outperform at Baird on ronde-cel potential
As previously reported, Baird initiated coverage of Lyell Immunopharma (LYEL) with an Outperform rating and $49 price target Lyell’s pipeline is headlined by ronde-cel, for which a pair of pivotal…
Lyell Immunopharma initiated with an Outperform at Baird
Baird initiated coverage of Lyell Immunopharma (LYEL) with an Outperform rating and $49 price target
Lyell Immunopharma Proxy statement: Proxy filing
Lyell Immunopharma filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Lyell Immunopharma Proxy statement: Proxy filing
Lyell Immunopharma filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Lyell Immunopharma Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing next-generation CAR T-cell therapies, with ronde-cel showing high response rates and a favorable safety profile in pivotal trials. Manufacturing is fully in-house, and commercial launch is targeted for next year. LYL273 for solid tumors is also progressing, with promising early data and upcoming disclosures.
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst
Lyell Immunopharma stock was down despite praise from a top Wall Street analyst on Friday.
Lyell Immunopharma initiated with a Buy at Needham
Needham initiated coverage of Lyell Immunopharma (LYEL) with a Buy rating and $44 price target The firm says the company’s ronde-cel is in the “pole position” for second-line diffuse large…
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma Registration statement: Registration filing
Lyell Immunopharma filed a registration statement on April 3, 2026, providing details about a securities offering with the SEC.
Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital
Lucid Capital analyst Christopher Liu raised the firm’s price target on Lyell Immunopharma (LYEL) to $39 from $32 and keeps a Buy rating on the shares following the fiscal 2025…
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma Annual report: Q4 2025
Lyell Immunopharma has published its Q4 2025 annual report on March 12, 2026.
Lyell Immunopharma Earnings release: Q4 2025
Lyell Immunopharma released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Lyell Immunopharma Transcript: The Citizens Life Sciences Conference 2026
Multiple pivotal trials are advancing for next-generation CAR T-cell therapies in lymphoma and colorectal cancer, with strong early efficacy and safety data. Major data updates are expected in H2, and financial resources are secured for continued development.
Lyell Immunopharma Transcript: Leerink Global Healthcare Conference 2026
Key updates include a new CFO hire, a $50M financing milestone, and strong clinical progress for the dual-targeted ronde-cel CAR T-cell therapy, which shows high response rates and a favorable safety profile. The company is also advancing a novel GCC CAR T-cell program for solid tumors, with promising early data and upcoming readouts.
Lyell Immunopharma appoints Smital Shah as CFBO
Lyell Immunopharma (LYEL) closed the sale of an additional $50M of shares of its common stock to investors from its July 2025 equity private placement of up to $100M, following…
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...